References
- Berg K. A new serum type system in man: the Lp system. Acta Pathol Microbiol Scand 1963; 59: 369–82
- Scanu A M, Fless G M. Lipoprotein(a). Heterogeneity and biological relevance. J Clin Invest 1990; 85: 1709–15
- Dalhén G H. Lp(a) lipoprotein in cardiovascular disease. Atherosclerosis 1994; 108: 111–26
- Liu A C, Lawn R M. Vascular interactions of lipoprotein(a). Curr Opin Lipidol 1994; 5: 269–73
- Lindhal G, Gersdorf E, Menzel H J, Duba C, Cleve H, Humphries S, et al. The gene for the Lp(a)-specific glycoprotein is closely linked to the gene for plasminogen on chromosome 6. Hum Genet 1989; 81: 149–52
- Boerwinkle E, Menzel H J, Kraft H G, Utermann G. Genetics of the quantitative Lp(a) lipoprotein trait. III. Contribution of Lp(a) glywpmtein phenotypes to normal lipid variation. Hum Genet 1989; 82: 73–8
- Utermann G, Menzel H J, Kraft H G, Duba H C, Kemmler H G, Seitz C. Lp(a) glycoprotein phenotypes: inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Inveat 1987; 80: 458–65
- Jenner J L, Ordovas J M, Lamon-Fava S, Schaefer M M, Wilson P WF, Castelli W P, et al. Effects of age, sex and menopausal status on plasma lipprotein (a) levels. The Framingham Offspring Study. Circulation 1993; 87: 1135–41
- Momsett J D, Nava M L, Ghanan K K, Gaubatz J W, Jones P H, Garber A J, . Metabolic relationship between plasma lipoprotein (a) and triglyceride. Atherosclerosis IX, O Stein, S Eisenberg, Y Stein, et al. R&L, Tel Aviv 1992; 123–6
- Ye S-Q, Trieu V N, Stiers D L, McConathy W J. Interactions of low density lipoproteins and other apolipoprotein B-containing lipoproteins with lipoprotein(a). J Biol Chem 1988; 263: 6337–43
- Manathy W J, Trieu V N, Kloer H U, Corder C N. Lp(a) and plasma triglyceride-rich lipoproteins. Klin Wochenschr 1990; 68(Suppl 22)117–19
- Bartens W, Rader D J, Talley G, Brewer B H. Decreased plasma levels of lipoprotein(a) in patients with hypertriglyceridemia. Atherosclerosis 1994; 108: 149–57
- Donders S HJ, Lustermans F AT, van Wersch J WJ. Low order correlations of lipoprotein (a) with other lipids and with coagulation and fibrinolysis parameters in hypertensive and diabetic patients. Blood Coagul Fibrinolysis 1992; 3: 249–56
- Ritter M M, Geiss H C, Richter W O, Schwandt P. Lipoprotein(a) concentrations and phenotypes in controls and patients with hypercholesterolemia or hypertriglyceridemia. Metabolism 1994; 43: 572–8
- Cohn J S, Lam C WK, Sullivan D R, Hensley W J. Plasma lipoprotein distribution of apolipoprotein (a) in the fed and fasted states. Atherosclerosis 1991; 90: 59–66
- Sandholzer C, Feussner G, Brunzell J, Utermann G. Distribution of apolipoprotein(a) in the plasma from patients with lipoprotein lipase deficiency and with type III hyperlipoproteinemia. No evidence for a triglycariderich precursor of lipoprotein(a). J Clin Invest 1992; 90: 1958–65
- Carlson L A, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med 1989; 226: 271–6
- Sentí M, Nogués X, Pedro-Botet J, Rubiés-Prat J, Vidal-Barraquer J. Lipoprotein profile in men with peripheral vascular disease. Role of intermediate density lipoproteins and apoprotein E phenotypes. Cirmlation 1992; 85: 30–6
- Pedro-Botet J, Senti M, Nogués X, Rubiés-Prat J, Roquer J, D'Olhaberriague, et al. Lipoprotein and apolipoprotein profile in men with ischemic stroke. Role of lipoprotein(a), triglyceride-rich lipoproteins, and apolipprotein E polymorphism. Stroke 1992; 23: 1556–62
- Havel R J. Role of triglyceride-rich lipoproteins in progression of atherosclerosis. Circulation 1990; 81: 694–6
- Pedro-Botet J, Sentí M, Auguet T, Nogués X, Rubiés-Prat J, Aubó C, et al. Apolipoprotein (a) genetic polymorphism and serum lipoprotein(a) concentration in patients with peripheral vascular disease. Atherderosis 1993; 104: 87–94
- Senti M, Pedro-Botet J, Rubiés-Prat J, Nogués X, Auguet T, Roquer J, et al. Influence of apolipo-protein(a) genetic polymorphism on serum lipo-protein(a) concentration in patients with ischemic cerebrovascular disease. Cerebrovasc Dis 1994; 4: 298–303
- Boerwinkle E, Leffert C C, Lin J, Lackner C, Chiesa G, Hobbs H H. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein (a) Concentrations. J Clin Invest 1992; 90: 52–60
- De Knijff P, Kaptein A, Boomsma D, Princen H MG, Frants R R, Havekes L M. Apolipoprotein E polymorphism affects plasma levels of lipo-protein(a). Atherosclerosis 1991; 90: 169–74
- Maeda S, Abe A, Seishima M, Makino K, Noma A, Kawade M. Transient changes of serum lipoprotein(a) as an acute phase protein. Atherosclerosis 1989; 78: 145–50
- Auguet T, Sentí M, Rubiés-Prat J, Pelegrí A, Pedro-Botet J, Nogués X, et al. Serum lipo-protein(a) concentration in patients with chronic renal failure receiving haemodialysis: influence of apolipoprotein (a) genetic polymorphism. Nephrol Dial Transplant 1993; 8: 1099–103
- Hajar K A, Gavish D, Breslow J L, Nachman R L. Lipoprotein (a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 1989; 339: 303–5
- Lakner C, Cohen J C, Hobbs H H. Molecular definition of the extreme size polymorphism in apolipo-protein(a). Hum Mol Genet 1993; 2: 933–40
- Sandhohr C, Saha N, Kark J D, Rees A, Jaross W, Diephger F, et al. Apo(a) isoforms predict risk for coronary heart disease: a study in six populations. Arterioscler Thromb 1992; 12: 1214–26